Cell-free DNA as a diagnostic marker for cancer: Current insights

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

The increasing knowledge of the molecular pathogenesis of cancer and the rapid development of new molecular techniques are promoting the study of early molecular alterations involved in cancer development in body fluids. Specific genetic and epigenetic alterations could be found in plasma, serum, and urine cell-free DNA (cfDNA) and could potentially be used as diagnostic biomarkers for several types of cancers. This review focuses on the role of cfDNA in diagnosis: a PubMed search was performed by selecting papers according to journal impact factor and robustness of statistical analysis. A comprehensive evaluation of “liquid biopsy”, including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.

Original languageEnglish
Pages (from-to)6549-6559
Number of pages11
JournalOncoTargets and Therapy
Volume9
DOIs
Publication statusPublished - Oct 25 2016

Fingerprint

DNA
Journal Impact Factor
Neoplasms
Body Fluids
Tumor Biomarkers
PubMed
Epigenomics
Urine
Biopsy
Serum

Keywords

  • Cancer
  • Cell-free DNA
  • Diagnosis
  • Liquid biopsy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{e4ce353a3ff5499c8b5e40ed1e9d97df,
title = "Cell-free DNA as a diagnostic marker for cancer: Current insights",
abstract = "The increasing knowledge of the molecular pathogenesis of cancer and the rapid development of new molecular techniques are promoting the study of early molecular alterations involved in cancer development in body fluids. Specific genetic and epigenetic alterations could be found in plasma, serum, and urine cell-free DNA (cfDNA) and could potentially be used as diagnostic biomarkers for several types of cancers. This review focuses on the role of cfDNA in diagnosis: a PubMed search was performed by selecting papers according to journal impact factor and robustness of statistical analysis. A comprehensive evaluation of “liquid biopsy”, including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.",
keywords = "Cancer, Cell-free DNA, Diagnosis, Liquid biopsy",
author = "Samanta Salvi and Giorgia Gurioli and {De Giorgi}, Ugo and Vincenza Conteduca and Gianluca Tedaldi and Daniele Calistri and Valentina Casadio",
year = "2016",
month = "10",
day = "25",
doi = "10.2147/OTT.S100901",
language = "English",
volume = "9",
pages = "6549--6559",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Cell-free DNA as a diagnostic marker for cancer

T2 - Current insights

AU - Salvi, Samanta

AU - Gurioli, Giorgia

AU - De Giorgi, Ugo

AU - Conteduca, Vincenza

AU - Tedaldi, Gianluca

AU - Calistri, Daniele

AU - Casadio, Valentina

PY - 2016/10/25

Y1 - 2016/10/25

N2 - The increasing knowledge of the molecular pathogenesis of cancer and the rapid development of new molecular techniques are promoting the study of early molecular alterations involved in cancer development in body fluids. Specific genetic and epigenetic alterations could be found in plasma, serum, and urine cell-free DNA (cfDNA) and could potentially be used as diagnostic biomarkers for several types of cancers. This review focuses on the role of cfDNA in diagnosis: a PubMed search was performed by selecting papers according to journal impact factor and robustness of statistical analysis. A comprehensive evaluation of “liquid biopsy”, including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.

AB - The increasing knowledge of the molecular pathogenesis of cancer and the rapid development of new molecular techniques are promoting the study of early molecular alterations involved in cancer development in body fluids. Specific genetic and epigenetic alterations could be found in plasma, serum, and urine cell-free DNA (cfDNA) and could potentially be used as diagnostic biomarkers for several types of cancers. This review focuses on the role of cfDNA in diagnosis: a PubMed search was performed by selecting papers according to journal impact factor and robustness of statistical analysis. A comprehensive evaluation of “liquid biopsy”, including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.

KW - Cancer

KW - Cell-free DNA

KW - Diagnosis

KW - Liquid biopsy

UR - http://www.scopus.com/inward/record.url?scp=84993967978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993967978&partnerID=8YFLogxK

U2 - 10.2147/OTT.S100901

DO - 10.2147/OTT.S100901

M3 - Review article

AN - SCOPUS:84993967978

VL - 9

SP - 6549

EP - 6559

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -